A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 G/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJGREN'S RELATED DRY EYE DISEASE

• Status: RECRUITING
• Trial end date: 2026-08-01

Summary

rhPRG4-Sjgren's-002 is a prospective multi-center study conducted in Australia to evaluate the safety and efficacy of topically-applied rhPRG4 in subjects with Sjgren's related Dry Eye Disease.

• Phase: PHASE2

Details

• Lead Sponsor: Lubris Bio Pty Ltd